BioSpace News Archive

Kintor Pharmaceutical Limited announced results of phase II clinical trial of pyrilutamide, a potential first-in-class topical drug developed by the company, in China for the treatment of adult female androgeneticalopecia.

Pyxis Oncology, Inc. announced that it has received clearance for its two Investigational New Drug applications from the U.S. Food and Drug Administration to initiate Phase 1 clinical trials.

SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) for SPVN06, its lead gene independent therapy for the treatment of retinitis pigmentosa (RP), a form of rod-cone dystrophy (RCD) and the most prevalent inherited retinal disease (IRD).

Renalytix plc announced additional highlights from the publication of data from a clinical utility study demonstrating that use of KidneyIntelX risk assessment in the primary care setting resulted in improved clinical decision making and observed clinical outcomes for 1,686 patients in the earliest stages of diabetic kidney disease.

OraSure Technologies, Inc., a global leader in the fight against HIV, will ring the closing bell for the Nasdaq Stock Market this afternoon in honor of World AIDS Day.

Athira Pharma, Inc. announced it will host a virtual research and development event titled “Enhancing the HGF/MET System to Fight Neurodegenerative Diseases,” on December 7, 2022, from 2:00 p.m. to 3:30 p.m. EST.

Humacyte, Inc. today announced presentations on the Company’s Human Acellular Vessel (HAV) by Ukrainian surgeon collaborators.

Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”), announced today the U.S. approval of a generic version of Perforomist® [1] (formoterol fumarate) Inhalation Solution.

Asuragen, a Bio-Techne brand and Oxford Nanopore Technologies plc, announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.

Senhwa Biosciences, Inc. announced that their first in class new drug Pidnarulex (CX-5461) has been successfully selected to the anticancer pipeline of NIH-sponsored NExT Program (NCI Experimental Therapeutics Program), which will foster the exploration of its therapeutic potential in unmet medical needs and advancement to market.